Sonic hedgehog in normal and neoplastic proliferation: Insight gained from human tumors and animal models

Current Opinion in Genetics and Development

Volumn 13, Issue 1, 2003, Pages 34-42

  Wetmore, Cynthia ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

SONIC HEDGEHOG PROTEIN; TRANSCRIPTION FACTOR;

ALLELE; APOPTOSIS; BASAL CELL CARCINOMA; CARCINOGENESIS; CELL CYCLE; CELL PROLIFERATION; GERM LINE; HUMAN; HYPERPLASIA; IONIZING RADIATION; MUSCLE TUMOR; MUTATION; NEOPLASM; NERVOUS SYSTEM TUMOR; NONHUMAN; PRIORITY JOURNAL; REVIEW; SKIN TUMOR; VERTEBRATE; WILD TYPE;

ANIMALIA; ERINACEIDAE; VERTEBRATA;

EID: 0037309324     PISSN: 0959437X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-437X(03)00002-9     Document Type: Review

References (76)

1. Hahn W.C., Weinberg R.A. Modelling the molecular circuitry of cancer. Nat. Rev. Cancer. 2:2002;331-341 A comprehensive discussion of the molecular mechanisms of the multistep process of tumorigenesis in humans and mice. This review concisely summarizes the complex body of experimental data on the process of malignant transformation and discusses the discrete histopathological steps and their correlation with specific genetic mutations. The authors also discuss the strengths and weaknesses of rodent models of human cancer and several of the important signaling pathways that differ between these species. Discussion of telomere shortening and other barriers to cellular immortalization are discussed in the context of cell culture as well as in vivo model systems.
2. Hanahan D., Weinberg R.A. The hallmarks of cancer. Cell. 100:2000;57-70.
3. Sherr C.J. Cancer cell cycles. Science. 274:1996;1672-1677.
4. Potter C.J., Turenchalk G.S., Xu T. Drosophila in cancer research. An expanding role. Trends Genet. 16:2000;33-39.
5. Van Dyke T., Jacks T. Cancer modeling in the modern era: progress and challenges. Cell. 108:2002;135-144.
6. Bale A.E., Yu K.P. The hedgehog pathway and basal cell carcinomas. Hum. Mol. Genet. 10:2001;757-762.
7. Goodrich L.V., Scott M.P. Hedgehog and patched in neural development and disease. Neuron. 21:1998;1243-1257.
8. Wechsler-Reya R., Scott M.P. The developmental biology of brain tumors. Annu. Rev. Neurosci. 24:2001;385-428 An extensive review of pathways governing normal development and neoplastic proliferation in the nervous system including the Shh/Ptc, Rb and Wnt signaling pathways. The authors address the differences among glial progenitors and the pathways directing their proliferation and the proliferation of cells in the neuronal lineage, such as cerebellar granule cells. Implications of control and deregulation of developmental pathways are discussed.
9. Ingham P.W., McMahon A.P. Hedgehog signaling in animal development: paradigms and principles. Genes. Dev. 15:2001;3059-3087.
10. Murone M., Rosenthal A., de Sauvage F.J. Sonic hedgehog signaling by the patched-smoothened receptor complex. Curr. Biol. 9:1999;76-84.
11. Nybakken K., Perrimon N. Hedgehog signal transduction: recent findings. Curr. Opin. Genet. Dev. 12:2002;503 This review discusses new experimental evidence from Drosophila on the interactions of Ptc and Smo in transducing the Hedgehog signal. Particularly, the interactions of molecules that direct the subcellular compartmentalization and activation of members of this signaling pathway.
12. Taipale J., Cooper M.K., Maiti T., Beachy P.A. Patched acts catalytically to suppress the activity of Smoothened. Nature. 418:2002;892-897 Evidence that Ptc and Smo are localized to different subcellular compartments and may not physically interact at the cell surface as previously believed. Ptc acts catalytically to suppress the constitutive activity of Smo signaling. The authors hypothesize that Ptc may control the activation of Smo by regulating the passage of a small molecule into the cell and act as a channel or transport molecule rather than the previously described physical interaction of the intracellular portions of Ptc and Smo.
13. Wechsler-Reya R.J., Scott M.P. Control of neuronal precursor proliferation in the cerebellum by Sonic Hedgehog. Neuron. 22:1999;103-114.
14. Ho K.S., Scott M.P. Sonic hedgehog in the nervous system: functions, modifications and mechanisms. Curr. Opin. Neurobiol. 12:2002;57-63.
15. Marti E., Bovolenta P. Sonic hedgehog in CNS development: one signal, multiple outputs. Trends Neurosci. 25:2002;89-96.
16. Hynes M., Stone D.M., Dowd M., Pitts-Meek S., Goddard A., Gurney A., Rosenthal A. Control of cell pattern in the neural tube by the zinc finger transcription factor and oncogene Gli-1. Neuron. 19:1997;15-26.
17. Dahmane N., Lee J., Robins P., Heller P., Ruiz i Altaba A. Activation of the transcription factor Gli1 and the Sonic hedgehog signalling pathway in skin tumours. Nature. 389:1997;876-881.
18. Dahmane N., Sanchez P., Gitton Y., Palma V., Sun T., Beyna M., Weiner H., Ruiz i Altaba A. The Sonic Hedgehog-Gli pathway regulates dorsal brain growth and tumorigenesis. Development. 128:2001;5201-5212 Activation of signaling in the Shh pathway by forced expression of the transcription factor Gli1 is sufficient to induce hyperproliferation in the developing frog embryo. (See also [17].).
19. Matise M.P., Joyner A.L. Gli genes in development and cancer. Oncogene. 18:1999;7852-7859.
20. Smyth I., Narang M.A., Evans T., Heimann C., Nakamura Y., Chenevix-Trench G., Pietsch T., Wicking C., Wainwright B.J. Isolation and characterization of human patched 2 (PTCH2), a putative tumour suppressor gene inbasal cell carcinoma and medulloblastoma on chromosome 1p32. Hum. Mol. Genet. 8:1999;291-297.
21. Pearse R.V. II, Vogan K.J., Tabin C.J. Ptc1 and Ptc2 transcripts provide distinct readouts of Hedgehog signaling activity during chick embryogenesis. Dev. Biol. 239:2001;15-29 Ptc1 and Ptc2 appear to have distinct anatomical distribution in the developing chick and show differential responsiveness to Hh signal.
22. Bai C.B., Auerbach W., Lee J.S., Stephen D., Joyner A.L. Gli2, but not Gli1, is required for initial Shh signaling and ectopic activation of the Shh pathway. Development. 129:2002;4753-4761 Initial but not subsequent signaling in Shh pathway requires Gli1. Suggestion that Gli2 plays prominent role in transducing ectopically active Shh signaling (as may occur in tumors) yet appears to serve a less activating role during normal proliferation of non-tumor cells.
23. Hahn H., Wicking C., Zaphiropoulous P.G., Gailani M.R., Shanley S., Chidambaram A., Vorechovsky I., Holmberg E., Unden A.B., Gillies S.et al. Mutations of the human homolog of Drosophila patched in the nevoid basal cell carcinoma syndrome. Cell. 85:1996;841-851.
24. •] independently report association of Patched mutations with basal cell nevus syndrome.
25. Gorlin R.J. Nevoid basal-cell carcinoma syndrome. Medicine (Baltimore). 66:1987;98-113.
26. Kimonis V.E., Goldstein A.M., Pastakia B., Yang M.L., Kase R., DiGiovanna J.J., Bale A.E., Bale S.J. Clinical manifestations in 105 persons with nevoid basal cell carcinoma syndrome. Am. J. Med. Genet. 69:1997;299-308.
27. Wicking C., Shanley S., Smyth I., Gillies S., Negus K., Graham S., Suthers G., Haites N., Edwards M., Wainwright B.et al. Most germ-line mutations in the nevoid basal cell carcinoma syndrome lead to a premature termination of the PATCHED protein, and no genotype-phenotype correlations are evident. Am. J. Hum. Genet. 60:1997;21-26.
28. Xie J., Murone M., Luoh S.M., Ryan A., Gu Q., Zhang C., Bonifas J.M., Lam C.W., Hynes M., Goddard A.et al. Activating Smoothened mutations in sporadic basal-cell carcinoma. Nature. 391:1998;90-92.
29. Lam C.W., Xie J., To K.F., Ng H.K., Lee K.C., Yuen N.W., Lim P.L., Chan L.Y., Tong S.F., McCormick F. A frequent activated smoothened mutation in sporadic basal cell carcinomas. Oncogene. 18:1999;833-836.
30. Taylor M.D., Liu L., Raffel C., Hui C.C., Mainprize T.G., Zhang X., Agatep R., Chiappa S., Gao L., Lowrance A.et al. Mutations in SUFU predispose to medulloblastoma. Nat. Genet. 31:2002;306-310 Report of germline Suppressor of Fused mutations in patients with predisposition to develop medulloblastoma. SUFU has been reported to direct subcellular localization of Gli1 and mutations in this gene interfere with export of Gli1 from the nucleus.
31. Ding Q., Fukami S., Meng X., Nishizaki Y., Zhang X., Sasaki H., Dlugosz A., Nakafuku M., Hui C. Mouse suppressor of fused is a negative regulator of sonic hedgehog signaling and alters the subcellular distribution of Gli1. Curr. Biol. 9:1999;1119-1122.
32. Pearse R.V. II, Collier L.S., Scott M.P., Tabin C.J. Vertebrate homologs of Drosophila suppressor of fused interact with the gli family of transcriptional regulators. Dev. Biol. 212:1999;323-336.
33. Pietsch T., Waha A., Koch A., Kraus J., Albrecht S., Tonn J., Sorensen N., Berthold F., Henk B., Schmandt N.et al. Medulloblastomas of the desmoplastic variant carry mutations of the human homologue of Drosophila patched. Cancer Res. 57:1997;2085-2088.
34. Pomeroy S.L., Tamayo P., Gaasenbeek M., Sturla L.M., Angelo M., McLaughlin M.E., Kim J.Y., Goumnerova L.C., Black P.M., Lau C.et al. Prediction of central nervous system embryonal tumour outcome based on gene expression. Nature. 415:2002;436-442 Large collaborative analysis of gene expression of PNET, medulloblastoma, gliomas to determine predictors of poor and favorable outcome. Evidence that different histologic subtypes of medulloblastoma are associated with different gene expression, suggesting different mechanisms of tumorigenesis.
35. Wolter M., Reifenberger J., Sommer C., Ruzicka T., Reifenberger G. Mutations in the human homologue of the Drosophila segment polarity gene patched (PTCH) in sporadic basal cell carcinomas of the skin and primitive neuroectodermal tumors of the central nervous system. Cancer Res. 57:1997;2581-2585.
36. Gilbertson R. Paediatric embryonic brain tumours. biological and clinical relevance of molecular genetic abnormalities. Eur. J. Cancer. 38:2002;675-685.
37. Kleihues P, Cavenee WK: World Health Organization Classification of Tumors: Pathology and Genetics of Tumors of the Nervous System. Lyon, France: IARCPress; 2000.
38. Packer R.J., Cogen P., Vezina G., Rorke L.B. Medulloblastoma: clinical and biologic aspects. Neuro-oncol. 1:1999;232-250.
39. Goldowitz D., Hamre K. The cells and molecules that make a cerebellum. Trends Neurosci. 21:1998;375-382.
40. Sidman R.L., Rakic P. Neuronal migration, with special reference to developing human brain: a review. Brain Res. 62:1973;1-35.
41. Ruiz i Altaba A., Sanchez P., Dahmane N. Gli and hedgehog in cancer: tumours, embryos and stem cells. Nat. Rev. Cancer. 2:2002;361-372.
42. Weiss W.A., Israel M., Cobbs C., Holland E., James C.D., Louis D.N., Marks C., McClatchey A.I., Roberts T., Van Dyke T.et al. Neuropathology of genetically engineered mice: consensus report and recommendations from an international forum. Oncogene. 21:2002;7453-7463 Consensus report from NCI-sponsored consortium on mouse models of human cancer of the nervous system. Several models of brain tumors are discussed as well as a summary of the available knowledge on the molecular basis of brain tumors.
43. Goodrich L.V., Milenkovic L., Higgins K.M., Scott M.P. Altered neural cell fates and medulloblastoma in mouse patched mutants. Science. 277:1997;1109-1113.
44. Hahn H., Wojnowski L., Zimmer A.M., Hall J., Miller G., Zimmer A. Rhabdomyosarcomas and radiation hypersensitivity in a mouse model of Gorlin syndrome. Nat. Med. 4:1998;619-622.
45. Bale A.E. Hedgehog signaling and human disease. Annu. Rev. Genomics. Hum. Genet. 3:2002;47-65.
46. Wetmore C., Eberhart D.E., Curran T. The normal patched allele is expressed in medulloblastomas from mice with heterozygous germ-line mutation of patched. Cancer Res. 60:2000;2239-2246 Expression of the wild-type patched allele persists in tumors arising in mice heterozygous for Ptc, suggesting the likelihood of involvement of modifier genes and/or additional mitogenic pathways.
47. Incardona J.P., Gaffield W., Lange Y., Cooney A., Pentchev P.G., Liu S., Watson J.A., Kapur R.P., Roelink H. Cyclopamine inhibition of Sonic hedgehog signal transduction is not mediated through effects on cholesterol transport. Dev. Biol. 224:2000;440-452.
48. Taipale J., Chen J.K., Cooper M.K., Wang B., Mann R.K., Milenkovic L., Scott M.P., Beachy P.A. Effects of oncogenic mutations in Smoothened and Patched can be reversed by cyclopamine. Nature. 406:2000;1005-1009.
49. Berman D.M., Karhadkar S.S., Hallahan A.R., Pritchard J.I., Eberhart C.G., Watkins D.N., Chen J.K., Cooper M.K., Taipale J., Olson J.M.et al. Medulloblastoma growth inhibition by hedgehog pathway blockade. Science. 297:2002;1559-1561 In vivo evidence of inhibition of Shh signaling may inhibit growth of tumor cells in allografts of mouse medulloblastoma to flank of mice. Authors also speculate on the possibility of epigenetic modification of Ptc mRNA as they were not able to detect Ptc mRNA in primary tumors but did detect the mRNA after passage of the tumor cells in culture for 48 hours in the presence of the demethylating agent 5-azacytidine.
50. Cook W.D., McCaw B.J. Accommodating haploinsufficient tumor suppressor genes in Knudson's model. Oncogene. 19:2000;3434-3438.
51. Quon K.C., Berns A. Haplo-insufficiency? Let me count the ways. Genes Dev. 15:2001;2917-2921.
52. Venkatachalam S., Shi Y.P., Jones S.N., Vogel H., Bradley A., Pinkel D., Donehower L.A. Retention of wild-type p53 in tumors from p53 heterozygous mice: reduction of p53 dosage can promote cancer formation. EMBO J. 17:1998;4657-4667.
53. Gutmann D.H., Loehr A., Zhang Y., Kim J., Henkemeyer M., Cashen A. Haploinsufficiency for the neurofibromatosis 1 (NF1) tumor suppressor results in increased astrocyte proliferation. Oncogene. 18:1999;4450-4459.
54. Calzada-Wack J., Kappler R., Schnitzbauer U., Richter T., Nathrath M., Rosemann M., Wagner S.N., Hein R., Hahn H. Unbalanced overexpression of the mutant allele in murine Patched mutants. Carcinogenesis. 23:2002;727-733 Evidence of overexpression of mutation Ptc allele in mice with rhabdomyosarcoma; persistent expression of wild-type Ptc allele.
55. +/- mice. Widespread persistent expression of Ptc mRNA in tumors as demonstrated by in situ hybridization of primary mouse medulloblastoma.
56. Aszterbaum M., Rothman A., Johnson R.L., Fisher M., Xie J., Bonifas J.M., Zhang X., Scott M.P., Epstein E.H. Jr. Identification of mutations in the human PATCHED gene in sporadic basal cell carcinomas and in patients with the basal cell nevus syndrome. J. Invest. Dermatol. 110:1998;885-888.
57. +/+ mice.
58. Aszterbaum M., Epstein J., Oro A., Douglas V., LeBoit P.E., Scott M.P., Epstein E.H. Jr. Ultraviolet and ionizing radiation enhance the growth of BCCs and trichoblastomas in patched heterozygous knockout mice. Nat. Med. 5:1999;1285-1291.
59. •].
60. •].
61. •].
62. •].
63. •] published the first reports of Ptc mutations in sporadic human medulloblastoma and BCCs. The authors also report cohorts of tumors with loss of heterozygosity at the PTCH allele as well as persistent expression of the wild-type allele.
64. Kogerman P., Krause D., Rahnama F., Kogerman L., Unden A.B., Zaphiropoulos P.G., Toftgard R. Alternative first exons of PTCH1 are differentially regulated in vivo and may confer different functions to the PTCH1 protein. Oncogene. 21:2002;6007-6016.
65. Hahn H., Wojnowski L., Specht K., Kappler R., Calzada-Wack J., Potter D., Zimmer A., Muller U., Samson E., Quintanilla-Martinez L. Patched target Igf2 is indispensable for the formation of medulloblastoma and rhabdomyosarcoma. J. Biol. Chem. 275:2000;28341-28344.
66. Moser A.R., Hegge L.F., Cardiff R.D. Genetic background affects susceptibility to mammary hyperplasias and carcinomas in Apc(min)/+ mice. Cancer Res. 61:2001;3480-3485.
67. Oro A.E., Higgins K.M., Hu Z., Bonifas J.M., Epstein E.H. Jr., Scott M.P. Basal cell carcinomas in mice overexpressing sonic hedgehog. Science. 276:1997;817-821.
68. ••].
69. Grachtchouk M., Mo R., Yu S., Zhang X., Sasaki H., Hui C.C., Dlugosz A.A. Basal cell carcinomas in mice overexpressing Gli2 in skin. Nat. Genet. 24:2000;216-217 Overexpression of Gli2 is sufficient to induce tumor formation in skin; evidence that Gli2 truncation of repressive domain can alter tumor phenotype. Suggests ectopic activation of Shh pathway may be mediated by Gli2 rather than Gli1.
70. Nilsson M., Unden A.B., Krause D., Malmqwist U., Raza K., Zaphiropoulos P.G., Toftgard R. Induction of basal cell carcinomas and trichoepitheliomas in mice overexpressing GLI-1. Proc. Natl. Acad. Sci. USA. 97:2000;3438-3443 Overexpression of Gli1 appears to be necessary and sufficient to induce skin tumors in mice; no additional mutation in other mitogenic pathways (ras, p53) is noted.
71. Fan H., Oro A.E., Scott M.P., Khavari P.A. Induction of basal cell carcinoma features in transgenic human skin expressing Sonic Hedgehog. Nat. Med. 3:1997;788-792.
72. Walter A.W., Pivnick E.K., Bale A.E., Kun L.E. Complications of the nevoid basal cell carcinoma syndrome: a case report. J. Pediatr. Hematol. Oncol. 19:1997;258-262 Patients with nevoid BCC syndrome develop basal cell nevi in areas within the therapeutic field of radiation therapy, suggesting sensitivity to ionizing radiation.
73. Pazzaglia S., Mancuso M., Atkinson M.J., Tanori M., Rebessi S., Majo V.D., Covelli V., Hahn H., Saran A. High incidence of medulloblastoma following X-ray-irradiation of newborn Ptc1 heterozygous mice. Oncogene. 21:2002;7580-7584.
74. 2/M phases of the cell cycle and persist in the cell cycle. Shh blocks p21CIP1/WAF1-induced growth arrest.
75. Barnes E.A., Kong M., Ollendorff V., Donoghue D.J. Patched1 interacts with cyclin B1 to regulate cell cycle progression. EMBO J. 20:2001;2214-2223.
76. 1 cyclin-Rb axis, resulting in persistent proliferation of granule neurons.